SCHEDULE: Federated Hermes Discloses 11.89% Stake in Forte Biosciences
Schedule 13G Amendment
Federated Hermes, Inc. and related entities have filed an amended Schedule 13G, disclosing beneficial ownership of 1,478,647 shares, representing 11.89% of Forte Biosciences, Inc.'s common stock.
Summary
- Federated Hermes, Inc., along with the Voting Shares Irrevocable Trust and its trustees (Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue), collectively reported beneficial ownership of 1,478,647 shares of Forte Biosciences, Inc. common stock.
- This aggregate amount represents 11.89% of the class of securities.
- Federated Hermes, Inc. and the Voting Shares Irrevocable Trust each hold sole voting and dispositive power over 1,478,647 shares.
- Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue each hold shared voting and dispositive power over 1,478,647 shares.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Forte Biosciences, Inc.
Sentiment
Score: 6
Explanation: The filing is a factual disclosure of beneficial ownership. The presence of a significant institutional stake (11.89%) by Federated Hermes, Inc. is generally viewed as a positive signal of confidence in the company, although the filing itself is neutral in tone.
Positives
- The disclosure of a significant 11.89% stake by a major institutional investor like Federated Hermes, Inc. can be interpreted as a vote of confidence in Forte Biosciences, Inc.'s long-term prospects.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders may view the significant institutional ownership as a positive indicator of investor confidence in Forte Biosciences, Inc.
Key Dates
| Date | Description |
|---|---|
| March 31, 2017 | Date of Power of Attorney for Thomas R. Donahue. |
| February 4, 2018 | Expiration date of Melissa Lamparski Bamonte's Notary Public commission. |
| January 10, 2023 | Date of Power of Attorney for Ann C. Donahue. |
| June 14, 2024 | Expiration date of Deanna L. Marley's Notary Public commission. |
| August 31, 2025 | Date of event which requires filing of this statement. |
| September 4, 2025 | Date of the Agreement for Joint Filing of Schedule 13G. |
| September 5, 2025 | Signature date for all reporting persons on the Schedule 13G. |
Recommendation
holdThis Schedule 13G filing primarily discloses beneficial ownership by Federated Hermes, Inc. and related entities. It does not provide operational performance, financial results, or strategic updates that would warrant a strong buy or sell recommendation. The significant institutional stake is a factual disclosure, suggesting a 'hold' stance as it confirms existing institutional interest without providing new performance-related catalysts.
Keywords
Forte Biosciences, Federated Hermes, beneficial ownership, Schedule 13G, common stock, institutional investor, equity stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.